Latigo Prices IPO at $345.6 Million, Debuts as Non-Opioid Pain Drug Developer
Latigo's $345.6 million IPO highlights Wall Street's bet on non-opioid pain therapies, marking a significant entry for the biotech firm into public…
Latigo's $345.6 million IPO highlights Wall Street's bet on non-opioid pain therapies, marking a significant entry for the biotech firm into public…
Trump’s tariff threat on pharmaceutical imports raises fears of generic drug shortages, hitting pharma stocks and potentially strengthening the US dollar amid…
Bayer divests contraceptive division stake to Apollo in a €3 billion deal, boosting its balance sheet and refocusing its pharmaceutical strategy.
Investors brace for Bayer court rulings after a $60 billion share price collapse.
Novo Nordisk and Eli Lilly stocks come under scrutiny as impending Ozempic and Mounjaro patent expirations threaten the GLP-1 revenue stream, forcing…
FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.